Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.

Date publication

novembre 2024

Journal

Lancet (London, England)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BOUSTANI Jihane

Tous les auteurs :
Bossi A, Foulon S, Maldonado X, Sargos P, MacDermott R, Kelly P, Fléchon A, Tombal B, Supiot S, Berthold D, Ronchin P, Kacso G, Salem N, Calabro F, Berdah JF, Hasbini A, Silva M, Boustani J, Ribault H, Fizazi K,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39580202

Résumé

The 2 × 2 PEACE-1 study showed that combining androgen-deprivation therapy with docetaxel and abiraterone improved overall and radiographic progression-free survival in patients with de novo metastatic castration-sensitive prostate cancer. We aimed to examine the efficacy and safety of adding radiotherapy in this population.

Mots clés

Humans, Male, Aged, Docetaxel, therapeutic use, Androstenes, therapeutic use, Androgen Antagonists, therapeutic use, Middle Aged, Prostatic Neoplasms, radiotherapy, Progression-Free Survival, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Treatment Outcome

Référence

Lancet. 2024 11 23;404(10467):2065-2076